Harmony Biosciences Holdings, Inc. (HRMY) — closed signal from October 12, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 10, 2026.
Predicted vs. what happened
What happened
Reached its target in 53 days.
The thesis — published October 12, 2025
After a research setback, the stock fell to a cheaper level. Short-term price action looks steadier, and investor mood remains solid. H.C. Wainwright kept a Buy rating after the Fragile X miss on 9-29, suggesting the core narcolepsy business still supports value. If the recent average price keeps flattening, shares could bounce over the next 0-3 months. Be aware that biotech names can swing widely, which adds risk.
Primary drivers
- Price looks beaten down, and near-term strength is starting to improve.
- Cash from narcolepsy drug sales helps set a base under the stock price.
- Buy rating held after the 9-29 trial miss, showing outside confidence.
- Buying in stages helps manage the sharp swings common in biotech.
How it played out
HRMY: target reached in 53 days
Lyra published HRMY at $26.54 on 2025-10-12 with a short-term thesis for 40% growth. The thesis pointed to a stock that looked beaten down after a research setback, steadier short-term price action, cash from narcolepsy drug sales, and a Buy rating held after the 9-29 trial miss. It also noted that biotech names could swing widely.
Inside the window, HRMY reached a peak of $40.87 on 2025-12-15, with a peak gain of 54%. It reached the $37.16 target in 53 days. The stock ended the window at $38.55, still above the target. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.